Literature DB >> 22140264

Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.

Benoit Visseaux1, Margarita Hurtado-Nedelec, Charlotte Charpentier, Gilles Collin, Alexandre Storto, Sophie Matheron, Lucile Larrouy, Florence Damond, Françoise Brun-Vézinet, Diane Descamps.   

Abstract

OBJECTIVE: The use of CCR5 inhibitors requires a tool to predict human immunodeficiency virus type 2 (HIV-2) tropism, as established in HIV-1. The aim of our study was to identify genotypic determinants of HIV-2 tropism located in the gp105 V3 loop.
METHODS: HIV-2 tropism phenotypic assays were performed on 53 HIV-2 clinical isolates using GFP expressing human osteosarcoma T4 [GHOST(3)] cell lines expressing CD4 and CCR5 or CXCR4 coreceptors. The gp105 V3 loop was sequenced and analyzed.
RESULTS: Thirty-four HIV-2 isolates were classified as R5, 7 as X4, and 12 as X4/R5 (dual). Substitution at residue 18 was always associated with a dual/X4 tropism (P < .00001). The following determinants were associated with dual/X4 tropism: a global net charge of more than +6 (P < .00001), V19K/R mutation (P < .00001), S22A/F/Y mutation (P < .002), Q23R mutation (P < .00001), and insertions at residue 24 (P < .00001), I25L/Y (P < .0004), R28K (P < .0004), and R30K (P < .014). These mutations were not found in R5 isolates, except R28K and R30K, which were detected in 4 and 5 R5 isolates, respectively. The 4 major genotypic determinants of dual/X4 tropism were mutation at residue 18, V19 K/R mutation, insertions at residue 24, and V3 global net charge.
CONCLUSIONS: We established a strong association between HIV-2 phenotypic tropism and V3-loop sequences, allowing for the prediction of R5- and/or X4-tropic viruses in HIV-2 infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22140264     DOI: 10.1093/infdis/jir698

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.

Authors:  Benoit Visseaux; Charlotte Charpentier; Margarita Hurtado-Nedelec; Alexandre Storto; Romain Antoine; Gilles Peytavin; Florence Damond; Sophie Matheron; Françoise Brun-Vézinet; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.

Authors: 
Journal:  J Int AIDS Soc       Date:  2016-10-23       Impact factor: 5.396

3.  A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.

Authors:  Selly Ba; Dana N Raugi; Robert A Smith; Fatima Sall; Khadim Faye; Stephen E Hawes; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

4.  Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2.

Authors:  Elena Heusinger; Katja Deppe; Paola Sette; Christian Krapp; Dorota Kmiec; Silvia F Kluge; Preston A Marx; Cristian Apetrei; Frank Kirchhoff; Daniel Sauter
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

5.  Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.

Authors:  Cheila Rocha; Rita Calado; Pedro Borrego; José Maria Marcelino; Inês Bártolo; Lino Rosado; Patrícia Cavaco-Silva; Perpétua Gomes; Carlos Família; Alexandre Quintas; Helena Skar; Thomas Leitner; Helena Barroso; Nuno Taveira
Journal:  Retrovirology       Date:  2013-10-24       Impact factor: 4.602

6.  HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage.

Authors:  Quirina Santos-Costa; Maria Manuel Lopes; Marta Calado; José Miguel Azevedo-Pereira
Journal:  Retrovirology       Date:  2014-11-25       Impact factor: 4.602

7.  HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells.

Authors:  Lise Chauveau; Isabel Puigdomenech; Diana Ayinde; Ferdinand Roesch; Françoise Porrot; Daniela Bruni; Benoit Visseaux; Diane Descamps; Olivier Schwartz
Journal:  Retrovirology       Date:  2015-01-13       Impact factor: 4.602

8.  A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support.

Authors:  Matthias Döring; Pedro Borrego; Joachim Büch; Andreia Martins; Georg Friedrich; Ricardo Jorge Camacho; Josef Eberle; Rolf Kaiser; Thomas Lengauer; Nuno Taveira; Nico Pfeifer
Journal:  Retrovirology       Date:  2016-12-20       Impact factor: 4.602

9.  HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man.

Authors:  Nicolas Cazals; Quentin Le Hingrat; Bruno Abraham; Patricia Da Silva; Laure Guindre; Sylvie Goffart; Florence Damond; Benoît Visseaux; Charlotte Charpentier; Sylvie Ranger-Rogez; Diane Descamps
Journal:  Open Forum Infect Dis       Date:  2018-09-11       Impact factor: 3.835

10.  Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.

Authors:  Benoit Visseaux; Charlotte Charpentier; Gilles Collin; Mélanie Bertine; Gilles Peytavin; Florence Damond; Sophie Matheron; Eric Lefebvre; Françoise Brun-Vézinet; Diane Descamps
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.